E-LIB Suche - Ergebnisse für: Nicolau, David P

1

Imipenem/relebactam pharmacokinetics in critically ill pati..:

Fratoni, Andrew J ; Kois, Abigail K ; Gluck, Jason A..
Journal of Antimicrobial Chemotherapy. 79 (2024) 5 - p. 1118-1125 , 2024

Link: https://doi.org/10.1093/..

2

Assessing the impact of meropenem exposure on ceftolozane/t..:

Fouad, Aliaa ; Nicolau, Samantha E ; Tamma, Pranita D...
Journal of Antimicrobial Chemotherapy. 79 (2024) 5 - p. 1176-1181 , 2024

Link: https://doi.org/10.1093/..

3

A New Dosing Frontier: Retrospective Assessment of Effluent..:

Lakshmipathy, Damini ; Ye, Xiaoyi ; Kuti, Joseph L...
Critical Care Explorations. 6 (2024) 4 - p. e1065 , 2024

Link: https://doi.org/10.1097/..

4

Assessing the in vivo impact of novel β-lactamase inhibitor..:

Ruiz, Victor H ; Gill, Christian M ; Nicolau, David P
Journal of Antimicrobial Chemotherapy. 79 (2024) 3 - p. 546-551 , 2024

Link: https://doi.org/10.1093/..

5

Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors..:

Fratoni, Andrew J ; Gethers, Matthew L ; Nicolau, David P.
Clinical Infectious Diseases. , 2024

Link: https://doi.org/10.1093/..

6

Deciphering the Efficacy of the β-Lactams in the Face of Me..:

Abdelraouf, Kamilia ; Gill, Christian M ; Gethers, Matthew...
Open Forum Infectious Diseases. , 2024

Link: https://doi.org/10.1093/..

7

Antimicrobial Stewardship in the Intensive Care Unit:

, In: Antimicrobial Stewardship in Non-Traditional Settings,

Chen, Iris H. ; Nicolau, David P. ; Kuti, Joseph L. - p. 161-183 , 2023

Link: https://doi.org/10.1007/..

8

Phenotypes, genotypes and breakpoints: an assessment of β-l..:

Asempa, Tomefa E ; Kois, Abigail K ; Gill, Christian M.
Journal of Antimicrobial Chemotherapy. 78 (2023) 3 - p. 636-645 , 2023

Link: https://doi.org/10.1093/..

9

Directed carbapenemase testing is no longer just for Entero..:

Gill, Christian M. ; Rajkotia, Poonam ; Roberts, Amity L...
Emerging Microbes & Infections. 12 (2023) 1 - p. , 2023

Link: https://doi.org/10.1080/..

10

Cefepime in vivo activity against carbapenem-resistant Ente..:

Fouad, Aliaa ; Gill, Christian M ; Simner, Patricia J..
Journal of Antimicrobial Chemotherapy. 78 (2023) 9 - p. 2242-2253 , 2023

Link: https://doi.org/10.1093/..

11

Prospective role of cefiderocol in the management of carbap..:

Kollef, Marin ; Dupont, Herve ; Greenberg, David E....
International Journal of Antimicrobial Agents. 62 (2023) 2 - p. 106882 , 2023

Link: https://doi.org/10.1016/..

12

2121. In vitro Synergy of the Combination of Sulbactam-Durl..:

Fouad, Aliaa ; Nicolau, David P ; Gill, Christian M
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

13

Physical compatibility of sulbactam/durlobactam with select..:

Ruiz, Victor H ; Shen, Yuwei ; Abouelhassan, Yasmeen...
American Journal of Health-System Pharmacy. 81 (2023) 1 - p. e21-e29 , 2023

Link: https://doi.org/10.1093/..

14

2165. Assessing the Impact of Meropenem Exposure on Ceftolo..:

Fouad, Aliaa ; Nicolau, Samantha ; Tamma, Pranita...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

15

In vivoefficacy & resistance prevention of cefiderocol in c..:

Gill, Christian M ; Santini, Debora ; Takemura, Miki...
Journal of Antimicrobial Chemotherapy. 78 (2023) 4 - p. 983-990 , 2023

Link: https://doi.org/10.1093/..